Evaluation of anti-tnf levels and anti-tnf antibodies in rheumatic diseases treated with adalimumab, etanercept and infliximab: results from a local registry

Autores: 

J. Rosas, F. Llinares, C. Santos-Ramírez, J.M. Senabre, G. Santos-Soler, X. Barber, M. Sánchez-Barrioluengo, E. Salas, J. Molina-García

Granada

8th International Congress on Autoinmmunity

Objectives: . To analyze clinical relevance of serum levels of adalimumab (ADA), etanercept (ETN) and infliximab (INF), and production of theirs antibodies (Abs).

Fecha de celbración: 

De Miércoles, 9 Mayo 2012 hasta Domingo, 13 Mayo 2012